Fig. 8

RORγt agonist treated Tc17 cells enhanced tumor CD8⁺ T cell infiltration in mice and IL17A is associated with immune cell infiltration in lung adenocarcinoma. a Schematic diagram of the experimental scheme. b ADT of RORγt agonist 8-074 treated Tc17 cells showed superior TGI in mice implanted with B16-OVA tumor cells. (N = 4 per group). **P < 0.01, by 2-way ANOVA. c RORγt agonist 8-074 enhances Tc17 cell migration in vivo. Two days after the last transfer into B16-OVA tumor-bearing mice, the number of CD45.1⁺ donor cells in the TDLN and tumor were analyzed by flow cytometry (*P < 0.05; **P < 0.01 and **** P < 0.0001). d RORγt agonist 8-074 increases tumor infiltration of CXCL10⁺ DC and CD8⁺ T cells (*P < 0.05; **P < 0.01 and ****P < 0.0001). e Left: IL17A expression correlationship with ITGAX expression; Right: IL17A expression correlationship with XCR1 expression in LUAD in the TCGA. f Left: CCL20 expression correlationship with CD8A expression; Right: CXCL10 and CD8A expression correlationship in LUAD samples from the TCGA. g Expression of CXCL10 and CCL20 in IL17A high expression and low expression groups in LUAD in the TCGA (***P < 0.001). h Schematic figure illustrating the mechanism of type 17 T cells modulating the TME. Data are shown as the mean ± SD of a representative experiment, and a student’s t-test was used for the statistical test. Experiments were repeated three times with consistent results